



February 2, 2018

Phillip R. Pylant, CEO
Village Compounding Pharmacy
975 Corbindale Road, Suite 100
Houston, TX 77024-2810

Dear Mr. Pylant:

We are enclosing a copy of the Establishment Inspection Report (EIR) for the inspection conducted at your facility, Village Compounding Pharmacy, located at 975 Corbindale Road, Suite 100, Houston, Texas 77024-2810, from March 20, 2017, to March 31, 2017, by the U.S. Food and Drug Administration (FDA). In addition, we are enclosing the letter (State Referral Letter) sent to the Texas State Board of Pharmacy for follow up.

When the Agency considers an inspection to be “closed” under 21 CFR 20.64(d)(3), it will release a copy of the EIR to the inspected establishment, and we have enclosed a copy with this letter.

The Agency continually works to make its regulatory process and activities more transparent for regulated industry. Releasing this EIR to you is part of this effort. The copy being provided to you comprises the narrative portion of the report; it may reflect redactions made by the Agency in accordance with the Freedom of Information Act (FOIA) and 21 CFR Part 20. This, however, does not preclude you from requesting and possibly obtaining any additional information under FOIA.

If there is any question about the released information, please contact Thao Ta, Compliance Officer, at 214-253-5217.

Sincerely,

John W. Diehl

-S

Digitally signed by John W. Diehl -S
DN: c=US, o=U.S. Government, ou=HHS,
ou=FDA, ou=People, cn=John W. Diehl -S,
0.9.2342.19200300.100.1.1=2000099727
Date: 2018.02.02 15:36:53 -06'00'

LCDR John W. Diehl, M.S.
Director, Compliance Branch
Office of Pharmaceutical Quality Operations,
Division II

U.S. Food & Drug Administration
Office of Pharmaceutical Quality Operations, Division II
4040 N. Central Expressway, Suite 300
Dallas, Texas 75204
www.fda.gov